pioglitazone has been researched along with Schizophrenia in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 9.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 5.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| "Pioglitazone did not increase weight or produce any other significant side-effects." | 2.78 | Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. ( Bark, N; Davis, JM; Dwivedi, S; Hu, Q; Jin, H; Li, C; Lohr, J; Mortiere, C; Shekhar, A; Smith, RC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sullivan, CR | 1 |
| Mielnik, CA | 1 |
| O'Donovan, SM | 1 |
| Funk, AJ | 1 |
| Bentea, E | 1 |
| DePasquale, EA | 1 |
| Alganem, K | 1 |
| Wen, Z | 1 |
| Haroutunian, V | 1 |
| Katsel, P | 1 |
| Ramsey, AJ | 1 |
| Meller, J | 1 |
| McCullumsmith, RE | 1 |
| Iranpour, N | 1 |
| Zandifar, A | 1 |
| Farokhnia, M | 1 |
| Goguol, A | 1 |
| Yekehtaz, H | 1 |
| Khodaie-Ardakani, MR | 1 |
| Salehi, B | 1 |
| Esalatmanesh, S | 1 |
| Zeionoddini, A | 1 |
| Mohammadinejad, P | 1 |
| Zeinoddini, A | 1 |
| Akhondzadeh, S | 1 |
| Smith, RC | 1 |
| Jin, H | 1 |
| Li, C | 1 |
| Bark, N | 1 |
| Shekhar, A | 1 |
| Dwivedi, S | 1 |
| Mortiere, C | 1 |
| Lohr, J | 1 |
| Hu, Q | 1 |
| Davis, JM | 1 |
| Edlinger, M | 1 |
| Ebenbichler, C | 1 |
| Rettenbacher, M | 1 |
| Fleischhacker, WW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function[NCT00231894] | Phase 4 | 56 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -6.82 |
| Placebo | -40.72 |
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -24.19 |
| Placebo | 15.19 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -13.33 |
| Placebo | -11.5 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.02 |
| Placebo | 24.20 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.52 |
| Placebo | 7.72 |
serum high density lipoprotein (HDL) (NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Piogltiazone | 4.62 |
| Placebo | -2.59 |
(NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -49.65 |
| Placebo | 30.99 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 32.56 |
| Placebo | -79.12 |
The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measure cognitive function in patients with schizophrenia. Range for list learning sub-score is 0 to 20 . Higher values indicate better performance. For change score (3 months -baseline) positive values indicate improved performance for this cognitive function and negative values indicate poorer performance on this cognitive function. (NCT00231894)
Timeframe: pre-treatment and 3 months of treatment
| Intervention | Units on RBANS scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | -1.11 |
2 trials available for pioglitazone and Schizophrenia
| Article | Year |
|---|---|
The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2016 |
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Antisocial Personality Disorder; Case-Control Stu | 2013 |
2 other studies available for pioglitazone and Schizophrenia
| Article | Year |
|---|---|
Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments.
Topics: Animals; Cluster Analysis; Down-Regulation; Drug Discovery; Energy Metabolism; Gene Knockdown Techni | 2019 |
Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series.
Topics: Adult; Aged; Antipsychotic Agents; Blood Glucose; Female; Homeostasis; Humans; Hyperglycemia; Hypogl | 2007 |